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Abstract
Background: At least 10% of the 56,000 annual new HIV infections in the United States are caused by individuals with acute
HIV infection (AHI). It unknown whether the health benefits and costs of routine nucleic acid amplification testing (NAAT)
are justified, given the availability of newer fourth-generation immunoassay tests.
Methods: Using a dynamic HIV transmission model instantiated with U.S. epidemiologic, demographic, and behavioral data,
I estimated the number of acute infections identified, HIV infections prevented, quality-adjusted life years (QALYs) gained,
and the cost-effectiveness of alternative screening strategies. I varied the target population (everyone aged 15-64, injection
drug users [IDUs] and men who have sex with men [MSM], or MSM only), screening frequency (annually, or every six
months), and test(s) utilized (fourth-generation immunoassay only, or immunoassay followed by pooled NAAT).
Results: Annual immunoassay testing of MSM reduces incidence by 9.5% and costs ,$10,000 per QALY gained. Adding
pooled NAAT identifies 410 AHI per year, prevents 9.6% of new cases, costs $92,000 per QALY gained, and remains
,$100,000 per QALY gained in settings where undiagnosed HIV prevalence exceeds 4%. Screening IDUs and MSM annually
with fourth-generation immunoassay reduces incidence by 13% with cost-effectiveness ,$10,000 per QALY gained.
Increasing the screening frequency to every six months reduces incidence by 11% (MSM only) or 16% (MSM and IDUs) and
costs ,$20,000 per QALY gained.
Conclusions: Pooled NAAT testing every 12 months of MSM and IDUs in the United States prevents a modest number of
infections, but may be cost-effective given sufficiently high HIV prevalence levels. However, testing via fourth-generation
immunoassay every six months prevents a greater number of infections, is more economically efficient, and may obviate the
benefits of acute HIV screening via NAAT.
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Introduction
Each year, more than 56,000 people in the United States
acquire HIV, many of whom are infected by individuals with acute
HIV infection (AHI), although the exact contribution of AHI is
uncertain.[1–4] AHI typically lasts for two to three months after
initial infection and individuals with AHI are exceptionally
infectious during this period due to rapid viral replication,[2,5,6]
because blood plasma viral loads are 100 times higher than during
asymptomatic infection.[7] Moreover, individuals with AHI are
likely status-unaware and may have had recent sexual contact with
one or more partners.
Prior studies indicate that individuals identified with AHI may
reduce risky sexual behavior.[8,9] Successfully identifying such
individuals during a short window may necessitate a frequent AHI
screening program. Third-generation enzyme linked immunosor-
bent assays (ELISA) do not detect antibodies for at least three
weeks after infection, and newer fourth-generation antigen-
antibody combination tests reduce this window by several days.
Before third-or fourth-generation assays detect infection, plasma
viral RNA may be detected with a nucleic acid amplification test
(NAAT). Individual NAAT screening is cost-prohibitive in many
settings, and several studies have developed and piloted pooled
NAAT testing, with the optimal pooling algorithm depending on
undetected AHI prevalence.[6,10–16] Pooled NAAT has been
shown to be cost-effective in a community clinic serving high-risk
men who have sex with men (MSM), although the study did not
compare testing with a fourth-generation immunoassay.[17]
Another study found that fourth-generation tests detect 62% of
samples classified as acute infection, suggesting that newer
immunoassays may obviate the need for NAAT testing.[18]
Recent guidelines recommend routine HIV screening of adults
and adolescents aged 13 to 64,[19] but it is unknown to what extent
concomitant efforts to increase AHI testing via NAAT will prevent
new infections and whether such a strategy is cost-effective.
Additionally, it is unclear whether NAAT testing should be utilized
given that a fourth-generation immunoassay was approved by the
U.S. Food and Drug Administration in June 2010.
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test(s) to administer, screening frequency, and target population,
could potentially prevent thousands of new HIV infections, adding
millions of life years to the population. The present study is the
first to compare the population-level health benefits and costs of
universal or targeted HIV screening with a fourth-generation
immunoassay, versus screening for acute infection with pooled
NAAT.
Methods
Study Design
The author’s previously published model [20,21] of HIV
transmission and disease progression was modified to include
acute HIV screening via NAAT. I instantiated the model using
demographic, epidemiologic, and cost data for the United States. I
then numerically simulated the epidemic over a 20-year time
horizon and estimated population-level outcomes, including HIV
incidence, AHI identified, quality-adjusted life years (QALYs),
costs, and cost-effectiveness. Additional model details are provided
as Supporting Information (Text S1).
Population
To account for variations in behavior and infection risk, the
adult population aged 15 to 64 years was subdivided based on
gender, risk behavior (MSM, injection drug users (IDU), MSM/
IDU, or low-risk), and male circumcision status (Table S1). By
integrating data on population sizes, number of people living with
HIV, and the distribution of infections by transmission mode,
undiagnosed HIV prevalence in each risk group was estimated: 4.3%
(MSM), 4.4% (male IDUs), 6.4% (MSM/IDUs), 5.9% (female
IDUs), 0.03% (low-risk men), and 0.07% (low-risk women).[1,22–
28] The HIV-infected population was further divided based on
disease stage, identification status, and antiretroviral treatment
status. The model included population entry and exit, non-HIV-
related mortality, and IDU-related mortality (Table S2).
HIV Transmission and Progression
An important public health benefit of HIV screening is reduced
transmission due to (1) effective counseling aimed at reducing risky
behavior, and (2) earlier ART initiation, which suppresses viral
load, reducing the chance of transmission.[29–35] The model was
explicitly designed to capture the population-level benefits of
reduced transmission, as well as the individual benefits of reduced
disease progression, morbidity, and mortality. The model includes
transmission via heterosexual and homosexual contact, and via
needle-sharing (Figure S1), and accounts for secondary transmission in
the population, which is a key advantage of a dynamic model.
Proportional mixing was assumed (i.e., individuals with many
partners are more likely to select a partner with many partners),
and transmission probabilities were varied based on gender,
disease stage, and ART status.
I assumed that AHI occurs for two months after initial
infection,[6,36] and that individuals with AHI are ten times as
infectious as in the asymptomatic period,[5,29,36–38] but both
assumptions were varied in sensitivity analysis.
HIV Screening
The model varies the population screened (all adults, MSM and
IDUs, or MSM only), frequency (annually or every six months),
and test sequence (third- or fourth-generation immunoassay, or
immunoassay with pooled NAAT if immunoassay-negative). The
latterattributeallowsdelineationofscreeningforprevalentinfection
(via fourth-generation assay), and testing for acute infection (via
NAAT). In the ‘‘status quo’’ scenario, current HIV screening rates
are assumed to persist for the model’s duration (Table 1).
Table 1. Key HIV screening parameters.
Parameter Value Range Source
Proportion tested in past 12 months (status quo)
High-risk individuals 23% 10–30% [44]
Low-risk individuals 10% 5–20% [44]
Symptom-based case finding per year
Symptomatic HIV 10% 0–30% [35]
AIDS 20% 10–60% [35]
Window period of detection (days)
3rd generation ELISA 22 14–40 [6,7,10]
4th generation immunoassay 17 10–28 [6,18]
NAAT 11 9–30 [6,11]
NAAT pooling algorithm sensitivity 95% 90–100% [39]
NAAT pooling efficiency (tests/specimen) 0.11 0.10–1.0 [2,39]
Proportion tested who receive NAAT test results 80% 50–100% [17]
Reduction in sexual partners if identified 50% 20–70% [8,9,45]
Cost of 3rd-generation ELISA $15 $10–$25 [11,35,43,46,47]
Cost of Western Blot confirmatory test $40 $25–$50 [47]
Cost of NAAT $120 $100–$150 [11–14,39,46]
Cost of quantitative viral load assay $120 $100–$140 [48,49]
Cost of HIV counseling $60 $40–$100 [35,42,43]
ELISA = enzyme linked immunosorbent assay; NAAT = nucleic acid amplification test.
doi:10.1371/journal.pone.0027625.t001
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the Architect HIV Ag/Ab Combo Assay (Abbott Diagnostics,
Wiesbaden, Germany), detects antigens on average 17 days
(the window period) after infection,[6,18] although I varied this
in sensitivity analysis (Figure S2). Before 17 days, individuals
would observe a negative immunoassay test and subsequently
be included in a pooled NAAT test, if applicable. After the
window period, individuals would receive a positive immunoassay
test and receive confirmatory testing via Western Blot; however,
they would not receive an AHI diagnosis. Because fourth-
generation assays may not be regularly used in all healthcare
settings, I also considered expanded screening with a third-
generation ELISA.
Pooled NAAT. To test for AHI, I assumed use of a qualitative
HIV RNA assay, such as the Aptima HIV-1 RNA Assay (Gen-
Probe Inc, San Diego, California), and that only persons with a
negative immunoassay are tested via pooled NAAT. Post-
infection, viremia levels increase exponentially from undetectable
to a level detectable by NAAT. I assumed that NAAT positivity
occurs 11 days after infection.[6,11] Given a lower limit of
detection of 30–50 copies/mL, the NAAT pooling sensitivity was
assumed to be 95% during the period before immunoassay
positivity.[39]
To ensure rapid turnaround of test results, I assumed a one-
stage pooling algorithm with pools containing ten samples,
resulting in an pooling efficiency (i.e., average number of tests
per specimen) of 0.11, assuming 0.5% of the HIV-infected
population has AHI.[2,39] Samples from positive pools are then
screened individually, and any individual sample with a positive
test undergoes a quantitative HIV RNA assay. I assumed that 80%
of individuals receive their test results,[17] and that persons
diagnosed with AHI receive post-test counseling and linkage
to care.
Health Outcomes and Costs
The mathematical model projects new HIV infections among
each risk group, as well as total QALYs for the population. I
included the costs of diagnostic services, confirmatory testing, and
counseling associated with each screening intervention (Table 1),
as well as future HIV-related and non-HIV-related healthcare
costs and ART costs, assuming a societal perspective. I assumed
that third- and fourth-generation assays cost the same, but I varied
this assumption in sensitivity analysis. The incremental cost-
effectiveness ratios (ICER) of each screening strategy were
calculated, to compare the costs and health benefits of each
strategy with the status quo and the next-best strategy on the cost-
effectiveness frontier. Importantly, the dynamic HIV epidemic
model captures the benefits of reduced secondary transmission in
cost-effectiveness estimates. Results are presented as cumulative
outcomes over a 20-year time horizon. Costs and QALYs were
discounted at an annual rate of 3%, with costs given in 2009 U.S.
dollars.[40]
Results
Annual HIV incidence (and incidence rates) among each
population were projected: 28,000 (0.7%) among MSM, 11,700
(1.2%) among IDUs, 5,100 (1.7%) among MSM/IDUs, and
15,500 (0.01%) among low-risk men and women, which are
broadly consistent with recent estimates.[23,25] Under the status
quo, an estimated 1.18 million new infections occur over 20 years
with approximately 158,000 infections (13.4%) caused by persons
with AHI.[3,5,41] Variations in the contribution of AHI were
examined in sensitivity analysis.
HIV Infections Prevented
Fourth-Generation Immunoassay. Annual screening of all
adults with fourth-generation immunoassay prevents 171,562
infections over 20 years (14.5% of the projected total); screening
every six months prevents 17.2% (Table 2). Strategies that screen
only key populations (MSM and IDUs) prevent a substantial
number of new infections: 12.8% if screened annually, or 15.3% if
screened every six months. Exclusively screening MSM reduces
incidence by 9.5% or 11.4% with annual or semi-annual
frequency, respectively. Although the feasibility of a frequent,
universal HIV screening program is questionable, these strategies
were considered to examine their theoretical benefit on the
epidemic.
Immunoassay and NAAT. Augmenting universal screening
with pooled NAAT prevents few additional infections over 20
years: 1,229 (0.1%) if testing annually or 1,683 (0.2%) if testing
every six months. Targeted NAAT testing of MSM and IDUs
prevents 1,171 to 1,609 infections, and screening only MSM
prevents 797 to 1,076 infections over 20 years. Because more than
50% of new infections in the United States occur among MSM,
targeted screening MSM prevents nearly two-thirds as many HIV
infections as universal testing. Of note, annual NAAT testing
prevents substantially fewer infections than a more frequent semi-
annual screening program with fourth-generation immunoassay
only.
Third-Generation ELISA. In general, expanded screening
with third-generation ELISA prevents slightly fewer new HIV
cases than with fourth-generation immunoassay (Table 3). For
example, annual screening of all adults with fourth-generation
assay prevents 171,562 infections over 20 years, compared to
171,071 with third-generation ELISA, a difference of less than
0.3%.
Acute Infections Identified
NAAT. As newer immunoassays become widely used, the
number of AHI identified via NAAT diminishes because the
newer assay (fourth-generation) identifies more infected persons
than the older test (third-generation ELISA) (Tables 2 and 3). For
example, annual NAAT testing of MSM and IDUs identifies 623
AHI per year, assuming NAAT follows a fourth-generation assay.
If third-generation ELISA is instead utilized, then NAAT detects
1,145 AHI. Screening twice as often (every six months) identifies
approximately 75% more AHI. This strategy has decreasing
returns because annual testing reduces overall incidence; hence,
there are fewer persons with AHI to identify six months later. A
similar effect occurs with screening every three months.
Immunoassay Only. In settings where NAAT is not utilized,
screening with only a fourth-generation assay identifies more
persons as HIV+ than with third-generation ELISA, because the
newer test detects antigen/antibodies earlier. For example, annual
fourth-generation testing of MSM and IDUs detects
approximately 400 additional HIV+ persons per year, compared
to screening with third-generation ELISA.
Cost-Effectiveness Analysis
Universal HIV screening with a fourth-generation immunoas-
say adds 2.3 to 2.7 million QALYs over 20 years at a cost of
$100,000 to $580,000 per QALY gained (Table 2). Targeted
screening of MSM and IDUs or MSM only offers more favorable
cost-effectiveness ratios: annual testing with immunoassay costs
less than $10,000 per QALY gained; screening every six months
costs less than $20,000 per QALY gained.
Because detection of AHI among low-risk populations is
uncommon, universal NAAT testing of all adults costs $3.2
Acute HIV Screening Cost-Effectiveness
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acceptable cost-effectiveness threshold. Annual NAAT screening
of MSM and IDUs or only MSM costs $80,000 to $92,000 per
QALY gained, which is generally considered cost-effective. Semi-
annual NAAT testing is less economically efficient, at a cost of up
to $140,000 per QALY gained. Of note, the analysis suggests that
screening MSM with fourth-generation immunoassay every six
months is more cost-effective than less frequent, annual testing
with NAAT.
Compared to screening with third-generation ELISA, pooled
NAAT is more cost-effective because of the longer window period
between NAAT and ELISA positivity (Table 3, Figures 1 and 2).
Annual NAAT testing of MSM costs $50,000 per QALY gained in
settings where third-generation ELISA is the dominant alternative,
but $92,000 per QALY gained relative to fourth-generation
testing.
Sensitivity Analysis
I evaluated variations in all model parameters, and the following
parameters most significantly affected results (Figure 3).
Window Period. I initially assumed that fourth-generation
assays detect infection after 17 days, but this window period is
uncertain. As newer tests shorten the time between initial infection
and test positivity, the relative benefits of NAAT decrease, which
worsens cost-effectiveness estimates (Figure 1). The cost-effectiveness
of NAAT improves as the immunoassay window period increases, or
as the NAAT window period decreases (Figure 2).
4.2 MSM HIV Prevalence
Undiagnosed HIV prevalence among MSM was estimated to
be 4.3% (with 12.5% overall HIV prevalence). As prevalence
decreases, the cost-effectiveness of NAAT worsens (Figure 4). If
undiagnosed HIV prevalence is only 1%, annual NAAT screening
identifies 160 AHI in MSM per year, at a cost of $200,000 per
QALY gained. In settings where undiagnosed HIV prevalence
exceeds 10%, annual NAAT testing of MSM costs less than
$50,000 per QALY gained, and semi-annual screening costs less
than $80,000 per QALY gained.
Impact of Acute HIV Infection. The base case con-
servatively estimated that AHI accounts for 13% of new HIV
infections in the U.S. If the relative contribution of AHI is greater,
due to a longer duration of AHI or greater infectivity during this
period, the cost-effectiveness of NAAT improves, and vice versa
(Table 4, Figure 3). For example, a three-month duration results in
20% of new cases due to AHI, and annual NAAT screening of
MSM costing $64,300 per QALY gained (base case: $92,200).
Receipt of Test Results. The base case assumed that 80% of
persons tested for AHI receive their test results. If only 50% of
MSM receive their results with annual NAAT testing, only 250
AHI are identified per year, for $147,000 per QALY gained
Table 2. Health and economic outcomes over 20 years with 4th-generation immunoassay.
Screening Strategy
AHI identified
with NAAT
per year
HIV infections prevented
over 20 years
(% of status quo)
Incremental
costs
(billions)
Incremental
QALYs
(millions) ICER ($/QALY)
vs status quo vs next best
Screen all adults
4G assay only
Annually --- 2171,562 (14.5%) $229.3 2.32 $98,700 $98,700
Every 6 months --- 2203,677 (17.2%) $471.3 2.74 $172,200 $583,000
4G assay & NAAT
Annually 817 2172,791 (14.6%) $271.6 2.34 $116,300 $3,174,000*
Every 6 months 1,427 2205,360 (17.4%) $556.0 2.76 $201,800 $4,700,600
Screen MSM and IDUs
4G assay only
Annually --- 2150,778 (12.8%) $11.9 1.87 $6,400 $6,400
Every 6 months --- 2181,278 (15.3%) $18.7 2.25 $8,300 $17,800
4G assay & NAAT
Annually 623 2151,949 (12.9%) $12.9 1.88 $6,900 $80,300*
Every 6 months 1,094 2182,887 (15.5%) $20.7 2.27 $9,100 $117,436
Screen MSM
4G assay only
Annually --- 2113,142 (9.5%) $8.0 1.37 $5,800 $5,800
Every 6 months --- 2135,147 (11.4%) $12.9 1.64 $7,900 $18,300
4G assay & NAAT
Annually 410 2113,939 (9.6%) $8.8 1.38 $6,400 $92,200*
Every 6 months 708 2136,223 (11.5%) $14.5 1.65 $8,800 $138,200
All outcomes are relative to the status quo (approximately 1.18 million new infections over 20 years). MSM = men who have sex with men; IDU = injection drug user;
4G assay = fourth-generation antigen-antibody combination assay; AHI = acute HIV infection; NAAT = nucleic acid amplification test; QALY = quality-adjusted life
year; ICER = incremental cost-effectiveness ratio compared to the status quo or next best strategy for each risk group. * = weakly dominated strategy (this strategy is
not on the cost-effectiveness frontier and is thus not economically efficient).
doi:10.1371/journal.pone.0027625.t002
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Screening Strategy
AHI identified
with NAAT
per year
HIV infections prevented
over 20 years
(% of status quo)
Incremental
costs
(billions)
Incremental
QALYs
(millions) ICER ($/QALY)
vs status quo vs next best
Screen all adults
3G ELISA only
Annually --- 2171,071 (14.5%) $229.3 2.32 $99,000 $99,000
Every 6 months --- 2203,295 (17.2%) $471.3 2.74 $172,400 $581,000
3G ELISA & NAAT
Annually 1,501 2173,340 (14.7%) $271.6 2.34 $116,000 $1,719,000*
Every 6 months 2,627 2206,409 (17.5%) $556.0 2.77 $201,000 $2,540,300
Screen MSM and IDUs
3G ELISA only
Annually --- 2150,286 (12.7%) $11.9 1.86 $6,400 $6,400
Every 6 months --- 2180,889 (15.3%) $18.7 2.25 $8,300 $17,700
3G ELISA & NAAT
Annually 1,145 2152,449 (12.9%) $12.9 1.89 $6,900 $43,500*
Every 6 months 2,014 2183,867 (15.6%) $20.7 2.28 $9,100 $63,179
Screen MSM
3G ELISA only
Annually --- 2112,649 (9.5%) $8.0 1.37 $5,800 $5,800
Every 6 months --- 2134,730 (11.4%) $12.9 1.64 $7,900 $18,200
3G ELISA & NAAT
Annually 754 2114,121 (9.7%) $8.8 1.38 $6,300 $49,600*
Every 6 months 1,303 2136,719 (11.6%) $14.5 1.66 $8,700 $74,100
All outcomes are relative to the status quo (approximately 1.18 million new infections over 20 years). MSM = men who have sex with men; IDU = injection drug user;
3G ELISA = third-generation enzyme linked immunosorbent assay; AHI = acute HIV infection; NAAT = nucleic acid amplification test; QALY = quality-adjusted life
year; ICER = incremental cost-effectiveness ratio compared to the status quo or next best strategy for each risk group. * = weakly dominated strategy (this strategy is
not on the cost-effectiveness frontier and is thus not economically efficient).
doi:10.1371/journal.pone.0027625.t003
Figure 1. One-way sensitivity analysis on the window period of detection. The cost-effectiveness of NAAT testing of MSM, given variations
in the window period of detection for the immunoassay. Testing occurs annually (black line) or every six months (grey line), and cost-effectiveness is
relative to screening with immunoassay only. MSM = men who have sex with men; NAAT = nucleic acid amplification test; QALY = quality-adjusted
life year.
doi:10.1371/journal.pone.0027625.g001
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$350,000 per QALY gained and is not economically efficient.
Behavior Change. A minimal reduction in risky sexual
behavior following testing and counseling attenuates some of the
benefits of expanded screening. With a 20% reduction in behavior,
the annual NAAT screening of MSM exceeds $130,000 per
QALY gained; with no reduction in behavior, the strategy exceeds
$600,000 per QALY gained.
Price of Fourth-Generation Immunoassay. Given a price
of $50 or $100, annual immunoassay testing of MSM costs $16,000
or $30,000 per QALY gained, respectively. At approximately
$315 per test, screening with fourth-generation tests or pooled
NAAT have similar cost-effectiveness.
Early ART Initiation. The recent HPTN 052 trial indicated
that early ART initiation can substantially reduce HIV trans-
mission in sero-discordant couples, and prior studies suggest that
Figure 2. Two-way sensitivity analysis on the window period of detection. The cost-effectiveness of annual NAAT testing of MSM, given
simultaneous variations in the window periods of detection for the immunoassay and NAAT, assuming the immunoassay detects infection after
NAAT. Cost-effectiveness is relative to annual screening with immunoassay only. MSM = men who have sex with men; NAAT = nucleic acid
amplification test; QALY = quality-adjusted life year.
doi:10.1371/journal.pone.0027625.g002
Figure 3. Tornado diagram with variations in model parameters. One-way sensitivity analysis of model parameters, where each horizontal
bar shows the range in cost-effectiveness given variations in each parameter value. The vertical line shows the base case cost-effectiveness ($92,000
per QALY gained). Cost-effectiveness of annual NAAT testing of MSM is relative to annual screening with fourth-generation immunoassay only. MSM
= men who have sex with men; NAAT = nucleic acid amplification test; QALY = quality-adjusted life year; ART = antiretroviral therapy; window
delta = days between NAAT and immunoassay positivity.
doi:10.1371/journal.pone.0027625.g003
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treatment improves health outcomes.[20] Although early ART
initiation is beyond the focus of this study, I estimated that an
annual screening program (via fourth-generation assay) for all
adults, coupled with 75% treatment initiation of all HIV+ persons
could avert 50-60% of projected future HIV cases. Adding pooled
NAAT prevents an additional 0.1% of cases, a very modest
improvement, because most of the benefit accrues from
maintaining high treatment coverage levels. This suggests that a
more sophisticated analysis of early treatment access, attrition,
adherence, and possible resistance should be performed.
Discussion
The present study estimated the population-level health benefits
and costs of alternative acute HIV screening strategies in the U.S.,
and the results highlight several important findings. This study is
the first to estimate the cost-effectiveness of expanded AHI
screening to all adults or key populations only, and to consider
expanded screening with fourth-generation immunoassay versus
pooled NAAT testing.
First, screening MSM annually with a fourth-generation assay
prevents 5,700 infections per year (9.5% of the total) for less than
$10,000 per QALY gained. Adding a pooled NAAT test following
a negative-immunoassay identifies 410 acute infections per year,
but reduces HIV incidence only modestly, for more than $92,000
per QALY gained. Doubling the NAAT testing frequency to every
six months identifies 75% more acute HIV infections but with a
cost-effectiveness exceeding $138,000 per QALY gained. Alterna-
tively, semi-annual screening with immunoassay only leads to an
overall greater increase in health benefits and is more econom-
ically efficient than annual NAAT testing. Screening MSM every
six months reduces annual HIV incidence by 6,800, adds 1.6
million QALYs to the population over 20 years, for less than
Figure 4. One-way sensitivity analysis on undiagnosed HIV prevalence among MSM. The cost-effectiveness of NAAT (solid line) or fourth-
generation immunoassay (dashed line) testing of MSM, given variations in undiagnosed HIV prevalence among MSM. Testing occurs annually (black
line) or every six months (grey line), and cost-effectiveness of NAAT is relative to screening with fourth-generation immunoassay only. MSM = men
who have sex with men; NAAT = nucleic acid amplification test; 4G = fourth-generation immunoassay; QALY = quality-adjusted life year.
doi:10.1371/journal.pone.0027625.g004
Table 4. Sensitivity analysis on the impact of acute HIV infection.
Duration
of AHI
Fraction of new
HIV infections
due to AHI
HIV infections prevented over
20 years (% of status quo) ICER ($/QALY)
Scenario
Screen MSM
annually
Screen MSM
every 6 months
Screen MSM
annually
Screen MSM
every 6 months
Base Case 2 months 13.4% 9.6% 11.5% $92,200 $138,200
Longer duration of AHI 3 months 20.0% 9.9% 11.8% $64,300 $95,400
Shorter duration of AHI 1 month 6.7% 9.3% 11.1% $141,200 $224,000
50% greater infectivity during AHI 2 months 17.9% 10.3% 12.3% $57,500 $81,300
50% lower infectivity during AHI 2 months 8.7% 9.0% 10.7% $162,000 $276,400
Longer duration of AHI & 50% greater infectivity 3 months 26.4% 11.1% 13.3% $34,000 $48,500
Shorter duration of AHI & 50% lower infectivity 1 month 4.3% 9.0% 10.8% $198,100 $358,300
All scenarios assume MSM are screened with a fourth-generation immunoassay and pooled NAAT.
MSM = men who have sex with men; AHI = acute HIV infection; NAAT = nucleic acid amplification test; QALY = quality-adjusted life year; ICER = incremental cost-
effectiveness ratio compared to screening with fourth-generation immunoassay only.
doi:10.1371/journal.pone.0027625.t004
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annual HIV screening via fourth-generation immunoassay is a
better use of resources than annual pooled NAAT.
Second, because MSM account for only 4% of the male
population but 68% of HIV cases among men,[24] targeted HIV
screening every six or 12 months is a particularly cost-effective
strategy. Screening IDUs as well prevents more infections with
similar cost-effectiveness ratios, although the uptake of frequent
screening among IDUs may be less feasible. Screening all adults
once per year reduces annual incidence by 15%, but this strategy is
less cost-effective than targeted screening, which is consistent with
prior studies.[35,42,43] The results suggest that even the most
optimistic HIV screening program where everyone is screened at
least once per year, prevents less than 20% of new infections and is
not sufficient to eliminate the HIV epidemic in the United States.
Although likely infeasible, I considered such a hypothetical
strategy to compare the efficiency of annual or semi-annual HIV
testing of all adults versus IDUs and/or MSM only. Augmenting
routine HIV screening with increased antiretroviral treatment
improves epidemic outcomes,[20] and earlier initiation of
treatment further reduces new cases.
Third, the cost-effectiveness of acute HIV screening depends on
each test’s window period of detection after initial infection. As
fourth-generation immunoassays become widely available, routine
testing of MSM with pooled NAAT is less cost-effective, assuming
the price of an immunoassay does not increase. If third-generation
ELISA tests remain the predominant alternative, pooled NAAT
may offer a valuable public health benefit, costing less than $75,000
per QALY gained with semi-annual screening.
A key factor driving the favorable cost-effectiveness ratios
associated with screening of MSM is high HIV prevalence among
this population, and by extension, high HIV incidence. At
undiagnosed HIV prevalence levels below 4%, annual NAAT
testing of MSM exceeds $100,000 per QALY gained. Policy-
makers aiming to allocate limited resources most effectively should
consider the local epidemic’s characteristics. If HIV prevention
programs, such as education campaigns, condom distribution, and
partnership notification, are shown to be effective in very low
prevalence settings, it may be optimal to continue investing in such
programs rather than scale-up testing.
The model projected that 13% of new cases are attributable to
acute HIV infection, although this contribution is uncertain,[4]
and cost-effectiveness improves dramatically as the relative impact
of AHI increases. If one-quarter of new cases is attributable to
AHI, then semi-annual NAAT testing of MSM costs less than
$50,000 per QALY gained. If AHI contributes to only 5% of HIV
cases, then NAAT testing costs $200,000 to $350,000 per QALY
gained.
Finally, the results suggest that efforts to reduce risky sexual
behavior following identification of AHI should be emphasized, as
failure to do so worsens cost-effectiveness estimates. To achieve the
full potential benefits of AHI screening, public health departments,
practitioners, and community-based clinics offering NAAT testing
should include concomitant efforts to counsel individuals with risk
behavior reduction and partner notification.
This study complements other recent HIV screening cost-
effectiveness studies. Hutchinson et al. found that the cost-effectiveness
of pooled NAAT versus third-generation ELISA depends sub-
stantially on local HIV prevalence levels.[17] Although the present
analysis includes the entire U.S. population and fourth-generation
immunoassay, the results are broadly consistent. Two independent
prior studies evaluated the cost-effectiveness of HIV screening
in the U.S., although the baseline incidence, undiagnosed HIV
prevalence, and test characteristics differed from the current
study.[35,43] Sanders et al. found that a routine screening program
prevented 21% of secondary cases,[35] and Paltiel et al. estimated
that annual screening reduced incidence by 5,100 out of 44,000–
60,000,[43] which are in line with the present study’s estimate of
10–15% depending on the target population. Additionally, both
studies only approximated reduced secondary HIV transmission,
which my dynamic transmission model is explicitly designed to
estimate.
Figure 5. Two-way sensitivity analysis on undiagnosed HIV prevalence among MSM. The cost-effectiveness of annual NAAT testing of MSM,
given simultaneous variations in undiagnosed HIV prevalence among MSM and the proportion receiving NAAT test results. Cost-effectiveness is relative to
screening with fourth-generation immunoassay only. MSM = men who have sex with men; NAAT = nucleic acid amplification test; QALY = quality-adjusted
life year.
doi:10.1371/journal.pone.0027625.g005
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most epidemic models, I simplified the complex dynamics of
disease transmission and partnership selection. Although I
stratified the population based on risk-status, I did not adopt a
more granular categorization, to maintain computational feasibil-
ity. I evaluated early ART initiation only in sensitivity analysis,
and given the high viremia levels during this period, ART
initiation during AHI may be a cost-effective strategy and further
investigation is warranted. I did not explicitly model partner
notification following AHI identification, although if individuals do
refer partners to be tested, this would likely improve cost-
effectiveness estimates. Finally, I ignored the potential effects of
sero-sorting after identification, which would again make the
results appear more favorable.
Quantifying the potential health benefits of pooled NAAT
testing for acute HIV infection is an important question as use of
newer antigen-antibody immunoassays becomes increasingly
widespread. In settings where undiagnosed HIV prevalence levels
exceed 4% among MSM, annual NAAT testing for acute HIV
infection costs less than $100,000 per QALY gained. However,
screening every six months with a fourth-generation immunoassay
is a more economically efficient use of program resources.
Augmenting acute HIV testing with early initiation of antiretro-
viral treatment may further justify the use of pooled NAAT testing,
and the cost-effectiveness of such a strategy should be explored.
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